These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3678067)

  • 41. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study of adverse reaction algorithms in a drug surveillance program.
    Louik C; Lacouture PG; Mitchell AA; Kauffman R; Lovejoy FH; Yaffe SJ; Shapiro S
    Clin Pharmacol Ther; 1985 Aug; 38(2):183-7. PubMed ID: 4017420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug utilization data in benefit analysis of drugs.
    Liljestrand A
    Acta Med Scand Suppl; 1984; 683():135-9. PubMed ID: 6204508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
    Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
    Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
    Madigan D; Ryan P
    Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
    [No Abstract]   [Full Text] [Related]  

  • 46. Adverse drug reaction reporting system: developing a well-monitored program.
    Kilarski DJ; Ziegler B; Coarse J; Buchanan C
    Hosp Formul; 1986 Sep; 21(9):949-52. PubMed ID: 10289704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of Adverse Drug Reactions using Medical Named Entities on Twitter.
    MacKinlay A; Aamer H; Yepes AJ
    AMIA Annu Symp Proc; 2017; 2017():1215-1224. PubMed ID: 29854190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Industrial drug-surveillance. Spontaneous notification: data collection, survey].
    Trunet P
    Rev Med Interne; 1986 Nov; Spec No():35-9. PubMed ID: 3809778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Round table: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry.
    Hum Reprod; 1987 Apr; 2(3):241-63. PubMed ID: 3597744
    [No Abstract]   [Full Text] [Related]  

  • 54. Social Media Listening for Routine Post-Marketing Safety Surveillance.
    Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
    Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 56. Postmarketing surveillance of adverse drug reactions.
    Castle WM; Lewis JA
    Br Med J (Clin Res Ed); 1984 May; 288(6428):1458-9. PubMed ID: 6426604
    [No Abstract]   [Full Text] [Related]  

  • 57. New thoughts on the "forgotten" aspect of antimicrobial stewardship: adverse event reporting.
    Hoffmann C; Khadem T; Schweighardt A; Brown J
    Pharmacotherapy; 2015 Jan; 35(1):59-63. PubMed ID: 25615401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises.
    Corrigan OP
    Soc Sci Med; 2002 Aug; 55(3):497-507. PubMed ID: 12144155
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.